---
title: "Weekly Recap | Legend Biotech +8.52%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300189422.md"
description: "LEGN.US gained 8.52% this week, closing at $19.11 and beating the S&P 500 by about 7.31 percentage points. The stock opened at $17.952 on Monday, pulled back to $18.275 on Wednesday, then pushed higher over the last two sessions, touching a weekly high of $19.69 on Friday before settling at $19.11. The weekly range came to 10.47%, with gains accelerating in the back half of the week."
datetime: "2026-09-26T06:37:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300189422.md)
  - [en](https://longbridge.com/en/news/300189422.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300189422.md)
generator: "portal-rs"
---

# Weekly Recap | Legend Biotech +8.52%, most brokers rate it buy

## The Week

LEGN.US gained 8.52% this week, closing at $19.11 and beating the S&P 500 by about 7.31 percentage points. The stock opened at $17.952 on Monday, pulled back to $18.275 on Wednesday, then pushed higher over the last two sessions, touching a weekly high of $19.69 on Friday before settling at $19.11. The weekly range came to 10.47%, with gains accelerating in the back half of the week.

## Key Events

The main thread this week was the long-term CARVYKTI data. On Friday, Legend Biotech presented five-year follow-up results showing that half of patients with relapsed/refractory multiple myeloma remained progression-free and alive five years after a single infusion. That came a day after the annual general meeting, where shareholders backed the board slate and expanded the equity incentive plan. Earlier in the week, an article on Wednesday asked whether a CEO appointment had shifted the investment narrative for Legend Biotech, though no formal announcement of a management change appears in the public record.

## Analyst Ratings

Legend Biotech is covered by 13 brokers: 3 rate it buy, 5 rate it overweight, and 5 rate it hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $46.9, roughly 145.4% above the latest close of $19.11. Targets range from $24 to $74, pointing to a wide spread of views. Within the biotech industry, the stock ranks 80th out of 506 names on broker ratings.

## The Week Ahead

Next week’s macro calendar is centred on housing and the labour market: FHFA house prices, the Case Shiller 20-city index, JOLTS job openings and consumer confidence all land on Tuesday. For biotech, these matter mostly as a backdrop for risk appetite rather than as direct drivers. On the company side, there are no confirmed earnings or major events on the calendar after this week’s CARVYKTI five-year readout; the next focus is whether regulatory or commercialisation progress follows.

## In Short

The combination this week is fairly clear: long-term CARVYKTI data reinforced the product narrative while the stock moved higher on rising volume. The consensus target sits far above spot, but with a target range of $24 to $74, the dispersion is large. The PB multiple is around 3.0x, and the latest daily capital snapshot shows modest net selling from large-lot flows while small and medium orders were net buyers. What to watch next is the commercialisation follow-through after the data readout, plus how next week’s macro releases shape risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)

## Related News & Research

- [Legend Biotech Stock Clears Key FDA Hurdle With LB2501 IND Approval](https://longbridge.com/en/news/302196684.md)
- [FDA Clears Legend Biotech's LB2501 CAR-T Therapy for Clinical Trials](https://longbridge.com/en/news/301974571.md)
- [RBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)](https://longbridge.com/en/news/298668225.md)
- [SpaceX Bulls Get Louder After Q3 Earnings Print, But One Firm Flags $475B Funding Gap](https://longbridge.com/en/news/302596793.md)
- [Micron introduces quarterly employee bonus tied to profits](https://longbridge.com/en/news/302675659.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**